From the April 2022 issue of HealthCare Business News magazine

Among the benefits of using Cardilogs’ technology are faster diagnostic reporting, decreases in the occurrence of reporting errors and streamlined clinician workflow and patient care.

Philips will expand Cardiologs’ reach to patients worldwide and utilize its technology to deliver the quadruple aim of an improved patient care experience, better health outcomes, improved staff experience, and lower cost of care.


Founded in 2014, Cardiologs consists of 70 employees, who will now join Philips. They will work in conjunction with Philips’ R&D lab in Paris to further its progress around the development of AI for medical care. Philips plans to assess Cardiologs’ branding strategy going forward.

"We look forward to the opportunity to expand the business as part of Philips, maintaining vendor-neutrality and continuing to work with third party vendors to drive further adoption of digital health solutions globally,” said Yann Fleureau, co-founder and CEO of Cardiologs, in a statement.

University of Minnesota Medical School examines prognostic value of cardiovascular MR
In October, researchers at the University of Minnesota Medical School touted the prognostic value of cardiovascular MR for diagnosing patients with suspected cardiac tumors.

Their support for the approach is based on the result of a first-of-its-kind, multicenter study they conducted that found CMR diagnosis to be accurate in 98.4% of patients.

Currently, if no cardiac tumor is found with the method, no further testing is conducted. But data validating the approach and its efficacy is limited. Chetan Shenoy, an associate professor in the Department of Medicine’s Cardiovascular Division at the U of M Medical School, told HCB News that he set out to address this in the study, which he led. “Our findings support the use of CMR as the technique of choice for the assessment of patients with suspected cardiac tumors, instead of multiple other techniques. CMR can be a "one-stop shop" for imaging to get the diagnosis and know what to do next for management. Of course, some patients who have tumors may need a biopsy, surgery, chemotherapy and/or radiation, but CMR can be the only imaging study they need.”

Shenoy and his colleagues used CMR on 903 patients at four different institutions. In addition to its high accuracy, CMR diagnosis was ranked as a powerful and independent predictor of death, with its prognostic value incremental to clinical factors.

Providers often rely on other forms of imaging such as transthoracic echocardiography, transesophageal echocardiography, CT imaging and PET imaging for assessing cases of suspected cardiac tumors. They often try more than one test depending on their personal preferences, expertise and local availability until they find the correct diagnosis. By validating the approach, the findings indicate that providers can avoid other tests and just apply CMR to collect all the data they need to treat such patients. This reduces time in diagnosing patients and also saves on cost.

April 2022 Magazine

Read more stories from the April 2022 issue

Cardiology Homepage